Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1957 2
1958 3
1959 1
1969 2
1971 1
1974 1
1976 1
1977 1
1982 1
1985 1
1986 2
1987 2
1988 2
1991 4
1992 2
1993 3
1994 6
1995 3
1996 4
1997 3
1998 2
1999 5
2000 6
2001 3
2002 5
2003 3
2004 3
2005 6
2006 8
2007 11
2008 14
2009 16
2010 15
2011 7
2012 8
2013 19
2014 20
2015 18
2016 21
2017 15
2018 21
2019 20
2020 20
2021 19
2022 16
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Results by year

Filters applied: . Clear all
Page 1
Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients with HIV.
Berenguer J, Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, López JC, Pinto-Martínez A, Moreno S, Montes ML, Iribarren JA, Orviz E, Portilla J, Villarroya F, Domingo P, Resino S; CoRIS cohort. Berenguer J, et al. Among authors: portilla j. J Infect Dis. 2024 Apr 1:jiae168. doi: 10.1093/infdis/jiae168. Online ahead of print. J Infect Dis. 2024. PMID: 38557859
Author Correction: Periodic Table of Food Initiative for generating biomolecular knowledge of edible biodiversity.
Jarvis A, Gallo-Franco J, Portilla J, German B, Debouck D, Rajasekharan M, Khoury C, Herforth A, Ahmed S, Tohme J, Arnaud E, Golden CD, Dawid C, de Haan S, DeClerck F, Feskens EJM, Fogliano V, Fritz G, Hald C, Hall R, Hart R, Henry A, Huang S, Hunter D, Imanbaeva B, Lowe A, Turner NJ, Jia G, Johnson E, Kalaiah G, Karboune S, Klade S, La Cerva GR, Lal V, Levy AA, Longvah T, Maeda-Yamamoto M, Minnis P, Nuti M, Octavio M, Osorio C, Pawera L, Peter S, Prasad R, Quave C, Shapiro HY, Sreeman S, Srichamnong W, Steiner R, Turdieva M, Ulian T, van Andel T, Wang R, Weissgold L, Yan J, de la Parra J. Jarvis A, et al. Among authors: portilla j. Nat Food. 2024 Mar;5(3):262. doi: 10.1038/s43016-024-00962-7. Nat Food. 2024. PMID: 38499749 No abstract available.
Periodic Table of Food Initiative for generating biomolecular knowledge of edible biodiversity.
Jarvis A, Gallo-Franco J, Portilla J, German B, Debouck D, Rajasekharan M, Khoury C, Herforth A, Ahmed S, Tohme J, Arnaud E, Golden CD, Dawid C, de Haan S, DeClerck F, Feskens EJM, Fogliano V, Fritz G, Hald C, Hall R, Hart R, Henry A, Huang S, Hunter D, Imanbaeva B, Lowe A, Turner NJ, Jia G, Johnson E, Kalaiah G, Karboune S, Klade S, La Cerva GR, Lal V, Levy AA, Longvah T, Maeda-Yamamoto M, Minnis P, Nuti M, Octavio M, Osorio C, Pawera L, Peter S, Prasad R, Quave C, Shapiro HY, Sreeman S, Srichamnong W, Steiner R, Turdieva M, Ulian T, van Andel T, Wang R, Weissgold L, Yan J, de la Parra J. Jarvis A, et al. Among authors: portilla j. Nat Food. 2024 Mar;5(3):189-193. doi: 10.1038/s43016-024-00941-y. Nat Food. 2024. PMID: 38459394 No abstract available.
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.
Santos JR, Domingo P, Portilla J, Gutiérrez F, Imaz A, Vilchez H, Curran A, Valcarce-Pardeiro N, Payeras A, Bernal E, Montero-Alonso M, Yzusqui M, Clotet B, Videla S, Moltó J, Paredes R. Santos JR, et al. Among authors: portilla j. Open Forum Infect Dis. 2023 Oct 31;10(11):ofad542. doi: 10.1093/ofid/ofad542. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38023553 Free PMC article.
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Podzamczer D, Imaz A, Lopez-Lirola A, Knobel H, Masiá M, Fanciulli C, Hernández C, Lagarde M, Gutierrez A, Curran A, Morano L, Montero-Alonso M, Troya J, Rigo R, Casadellà M, Navarro-Alcaraz A, Ardila F, Parera M, Bernal E, Echeverria P, Estrada V, Hidalgo-Tenorio C, Macias J, Prieto P, Portilla J, Valencia E, Vivancos MJ, Rivero A. Podzamczer D, et al. Among authors: portilla j. J Antimicrob Chemother. 2023 Nov 6;78(11):2696-2701. doi: 10.1093/jac/dkad285. J Antimicrob Chemother. 2023. PMID: 37725999 Clinical Trial.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
337 results